Proton Versus Photon Therapy in Head and Neck Squamous Cell Carcinomas.

Recruiting now · Phase 3

Conditions studied: HNSCC

In brief

A national, randomized, clinical trial (phase III) investigating radiotherapy with protons compared with photons for patients with squamous cell carcinoma of the head and neck area eligible for radiotherapy, either radical or postoperative, with curative intent. Comparative dose plans with protons and photons will be prepared, and the probability of toxicity evaluated with NTCP models. Patients with presumed benefit from protons will be randomized 1:1 to treatment with protons or photons. The number of randomized participants will be 400. The primary endpoint is "combined toxicity burden" - dry mouth, difficulty swallowing, pain and affected speech in the period after the end of radiotherapy to 12 months after treatment.

Key facts

Study ID

NCT07580300

Run by

Oslo University Hospital

People needed

400

Starts

2026-04-28

Expected to finish

2055-04-28

Last updated by the study team

2026-05-15

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent.
• Age ≥ 40 years.
• Histological or cytological verified squamous cell carcinoma of the following head and neck regions; oral cavity, oropharynx, hypopharynx or larynx.
• Planned for standard radiotherapy with curative intent, either as definitive or postoperative treatment with or without concomitant chemotherapy (cisplatin).
• ECOG performance status 0-2.
• Ability to fill in patient questionnaires and comply with study procedures.
• Able to answer questionnaires in Norwegian or English.
• Willing to travel to Oslo or Bergen for proton therapy if randomised to experimental arm.

You may not qualify if…

• Glottic cancers, cT1-T2 cN0 cM0.
• Nasopharyngeal carcinomas, sino-nasal cancers, and head and neck salivary gland carcinomas.
• Distant metastasis.
• Previous radiotherapy to the head and neck.
• Patients with pacemakers and/or implanted defibrillators.
• Prior malignancy within the last 5 years. Not including radically resected non-melanoma skin cancer or low-risk early-stage prostate cancer.
• Not able to participate due to equipment restrictions (weight limit treatment board 150 kg).
• Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could, at the investigator's opinion, interfere with the participant's safety or study participation.

Where it is running

• Oslo University Hospital, Radiumhospitalet — Oslo, Norway (enrolling)
• Haukeland University Hospital — Bergen, Norway
• University Hospital of Northern Norway — Tromsø, Norway
• St. Olavs Hospital — Trondheim, Norway

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.